Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts (DATA)

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2013 by Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
Sponsor:
Information provided by (Responsible Party):
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
ClinicalTrials.gov Identifier:
NCT01928407
First received: June 19, 2013
Last updated: August 20, 2013
Last verified: August 2013
  Purpose

A phase IV, prospective, multicenter , randomized open label, 48 weeks study to evaluate the antiretroviral efficacy and safety of atazanavir/ritonavir or darunavir/ritonavir, each in combination with a fixed dose of tenofovir disoproxil fumarate- emtricitabine in HIV-1-infected treatment-naïve subjects with CD4 counts below 200 µL.


Condition Intervention Phase
HIV-1 Infection
Immunosuppression-related Infectious Disease
Drug: DARUNAVIR
Drug: ATAZANAVIR
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase IV, Prospective, Multicenter , Randomized Open Label, 48 Weeks Study to Evaluate the Antiretroviral Efficacy and Safety of Atazanavir or Darunavir,Each in Combination With a Fixed Dose of Tenofovir Emtricitabine in HIV-1-infected Treatment-naïve Subjects With CD4counts Below 200 µL.

Resource links provided by NLM:


Further study details as provided by Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba:

Primary Outcome Measures:
  • Viral load of HIV-1 < 50 cp/ml [ Time Frame: 48 weeks ] [ Designated as safety issue: Yes ]
    To evaluate the virological efficacy and safety at week 48 of 2 regimens atazanavir/ritonavir (ATZ/r) 300/100 mg or darunavir/ritonavir (DRV/r) 800/100 mg, each in combination with a fixed-dose of tenofovir/emtracitabine in HIV-1 treatment-naïve subjects with CD4 counts below 200 µL


Secondary Outcome Measures:
  • • Proportion of subjets with virologic efficacy [ Time Frame: 24 weeks ] [ Designated as safety issue: Yes ]
    • Proportion of subjets with virologic efficacy (viral load of HIV-1 <50 cp/ml)

  • • Proportion of subjects with confirmed virologic failure [ Time Frame: 24 weeks ] [ Designated as safety issue: Yes ]
    • Proportion of subjects with confirmed virologic failure (viral load > 50 cp/ml on 2 consecutive mesures)

  • Viral lod of HIV-1 on seminal fluid [ Time Frame: W00,W4 et W48 ] [ Designated as safety issue: Yes ]
    • Evaluate the viral load of HIV-1 at week 0, week 4 and week 48 on the seminal fluid (substudy)

  • Immunologic response [ Time Frame: W-4,W2,W4,W12,W24 and W48 ] [ Designated as safety issue: Yes ]
    • Evaluate the immunologic response by the CD4 mesearement at W-4,W2,W4,W12,W24 and W48

  • Differenciation and activation of lymphocytes [ Time Frame: W0,W2,W4,W12,W24 and W48 ] [ Designated as safety issue: Yes ]
    At the end of the study, in a central lab, we will measure some inflammation and activation markers (CD69, HLA-DR, CD38, annexine V, IL-6, CD14s, IL-7 plasma) of lymphocytes CD4 and CD8(with the plasmatheque collected during the study)

  • Pharmacokinetics evaluation of the drugs in plasma [ Time Frame: W4,W24 and W48 ] [ Designated as safety issue: Yes ]
    Measure of drugs (atazanir and darunavir) concentration (24 hours after taking treatment)in plasma at week 4, 24, and 48

  • Pharmacokinetic evaluation of the drugs in semen [ Time Frame: W4 and W48 ] [ Designated as safety issue: Yes ]
    Measure of drugs (atazanir and darunavir) concentration (24 hours after taking treatment)in semen at week 4 and 48

  • • Evaluate the relationship of bilirubinemia with atazanavir [ Time Frame: W4 and W48 ] [ Designated as safety issue: Yes ]
    Evaluate the relationship of the evolution of the measure of bilirubinemia (collected during study) with the concentration of atazanavir in blood

  • Fasting glucose, lipids and insulin [ Time Frame: W48 ] [ Designated as safety issue: Yes ]
    • Change from baseline in fasting lipids, fasting glucose and insulin over time in the 2 arms

  • Clinic and biologic tolerance [ Time Frame: W48 ] [ Designated as safety issue: Yes ]

    Evaluate the clinic and biologic tolerance between the 2 regimens (adverse event and some biologic measure will be collected for this evaluation).

    We will see in two arms if there are more adverse event or biological event.


  • Sexual behaviour [ Time Frame: W0,W24 et W48 ] [ Designated as safety issue: Yes ]
    • Compare sexual behaviour between the regimens (substudy with a questionnary)

  • Adherence patient satisfaction [ Time Frame: W2,W24 et W48 ] [ Designated as safety issue: No ]
    • Compare adherence patient satisfaction between the regimens (with questionnary)


Estimated Enrollment: 120
Study Start Date: March 2011
Estimated Study Completion Date: February 2014
Estimated Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ATAZANAVIR
The patient included in this Group 1 will receive their first antiretroviral regimen included : ATV + TDF/FTC (or Abacavir/Lamivudine, [ABC/3TC], if contre indicated of TDF/FTC) The dose : atazanavir/ritonavir 300/100mg/day and TDF/FTC 245 /200 mg day, 3 pills once a day, during 48 weeks during a meal
Drug: ATAZANAVIR
The patient included will receive their first antiretroviral regimen included the atazanavir treatment in combination with 2 others molecules
Other Name: REYATAZ
Experimental: DARUNAVIR
The patients included in this Group 2 will receive their first antiretroviral regimen included Group 2 : DRV+ TDF/FTC (or ABC/3TC if contre-indicated of TDF/FTC) The dose : darunavir/ritonavir 800/100mg/day and TDF/FTC 245 /200 mg day, 4 pills once a day, during 48 weeks during a meal
Drug: DARUNAVIR
The patient included will receive their first antiretroviral regimen included the darunavir treatment in combination with 2 others molecules
Other Name: Prezista

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Male or female, aged > 18 years of age
  • HIV-1 infection determined by a positive ELISA and confirmed by Western blot
  • Plasma HIV-RNA > 1 000 c/mL
  • CD4+T cell count < =200 cells/mm3 at the time of screening, or < =250 cells/mm3 if the CD4 count was <200 cells/mm3 12 weeks before screening
  • Women of childbearing potential must agree to use an effective method of barrier contraception or have documented sterility
  • Subjects must have medical insurance throught the Securite Sociale
  • Ability to understand and provide written informed consent

Exclusion Criteria

  • Acute opportunistic infection within the past two weeks
  • HIV-2 infection
  • Pregnant woman
  • Any subject with drug resistance mutations at screening
  • Any subject with a grade 3 or greater clinical or laboratory adverse event at screening
  • Any subject who has received antiretoviral therapy except for prevention of mother to child transmission and patients who has received post exposure prophylaxis for a a month or less
  • Calculated creatinine clearance < 60/mL as estimated by the Cockcroft- Gault equation
  • Patients in the opinion of the investigator that are unlikley to be able to follow study instructions
  • Any subject unable to take antiretroviral medication for whatever reason
  • Any subject taking a treatment or medication that is contraindicated when co-administered with any arm or drug in the treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01928407

Contacts
Contact: Aïda AB BENALYCHERIF +33.1.40.25.63.65 aida.benalycherif@gmail.com
Contact: Karine KA AMAT +33.1.40.25.63.52 karine.amat@hotmail.fr

Locations
France
Hopital Zobda Quitman Recruiting
Fort-de-france, Martinique, France, 97261
Contact: André AC CABIE, PhD    +33.5.96.55.23.01    andre.cabie@chu-fort-de-france.fr   
Principal Investigator: André AC CABIE, PhD         
Centre Hospitalier D'Argenteuil Recruiting
Argenteuil, France, 95107
Contact: Juliette JG GERBE    +33.1.34.23.22.18    juliette.gerbe@ch-argenteuil.fr   
Principal Investigator: Virginie VM MASSE, PhD         
Hopital Saint-Jacques Recruiting
Besancon, France, 25000
Contact: Véronique VB BOURDEAUX, PhD    +33.3.81.21.85.33    c1bourdeaux@chu-besancon.fr   
Principal Investigator: Bruno BH HOEN, PhD         
Hopital Avicenne Recruiting
Bobigny, France, 93000
Contact: Gaëlle GO OBENGA, PhD    +33.1.48.95.54.21    gaelle.obenga@avc.aphp.fr   
Principal Investigator: Olivier OB BOUCHAUD, PhD         
Hopital Jean Verdier Recruiting
Bondy, France, 93143
Contact: Mufide MK KAHRAMAN    +33.1.48.02.63.11    mufide.kahraman@jvr.aphp.fr   
Principal Investigator: Vincent VJ JEANTILS, PhD         
Hopital Saint-Andre Recruiting
Bordeaux, France, 33075
Contact: Sabrina SC CALDATO    +33.5.56.79.57.33    sabrina.caldato@chu-bordeaux.fr   
Principal Investigator: Patrick PM MERCIE, PhD         
Chu Cote de Nacre Recruiting
Caen, France, 14033
Contact: Philippe PF FERET    +33.2.31.06.50.87    feret-p@chu-caen.fr   
Principal Investigator: Renaud RV VERDON, PhD         
Hopital Louis Mourier Recruiting
Colombes, France, 92700
Contact: Feng FZ ZENG    +33.1.47.60.61.84    feng.zeng@lmr.aphp.fr   
Principal Investigator: Emmanuel EM MORTIER, PhD         
Hopital Le Bocage Recruiting
Dijon, France, 21034
Contact: Sandrine ST GOHIER    +33.3.80.29.36.31    sandrine.gohier@chu-dijon.fr   
Principal Investigator: Lionel LP PIROTH, PhD         
Hopital Raymond Poincare Recruiting
Garches, France, 92380
Contact: Huguette HB BERTHE    +33.1.47.10.46.65    huguette.berthe@rpc.aphp.fr   
Principal Investigator: Pierre PT DE TRUCHIS, PhD         
C.H.D de Vendee Recruiting
La Roche Sur Yon, France, 85925
Contact: Isabelle IS SUAUD    +33.2.51.37.49.66    hjmpu@chd-vendee.fr   
Principal Investigator: Philippe PP PERRE, PhD         
Hopital Dupuytren Recruiting
Limoges, France, 87000
Contact: Claire CG GENET, PhD    +33.5.55.05.66.44    claire.genet@unilim.fr   
Principal Investigator: Claire CG GENET, PhD         
Hopital Sainte-Marguerite Recruiting
Marseille, France, 13274
Contact: Alena AI IVANOVA    +33.4.91.74.61.63    alena.ivanova@mail.ap-hm.fr   
Principal Investigator: Isabelle IM POIZOT-MARTIN, PhD         
Centre Hospitalier de Melun Recruiting
Melun, France, 77011
Contact: Ali AK KARA, PhD    +33.1.64.71.60.96    ali.kara@ch-melun.fr   
Principal Investigator: Ali AK KARA, PhD         
Hopital L'Archet Recruiting
Nice, France, 06202
Contact: Marie-Ange MS SERINI    +33.4.92.03.90.22    serini.ma@chu-nice.fr   
Principal Investigator: Jacques JD DURANT, PhD         
Hopital Europeen Georges Pompidou Recruiting
Paris, France, 75908
Contact: Erika EB BOURZAM    +33.1.56.09.33.03    erika.bourzam@egp.aphp.fr   
Principal Investigator: Laurence LW WEISS, PhD         
Hopital Necker Recruiting
Paris, France, 75015
Contact: Fatima FT TOUAM    +33.1.44.49.40.28    fatima.touam@nck.aphp.fr   
Principal Investigator: Claudine CD DUVIVIER, PhD         
Hopital Pitie-Salpetriere Recruiting
Paris, France, 75013
Contact: Patricia PB BOURSE    +33.1.42.16.02.93    patricia.bourse@psl.aphp.fr   
Principal Investigator: Christine CK KATLAMA, PhD         
Hopital Lariboisiere Recruiting
Paris, France, 75010
Contact: Maguy MP PARRINELLO    +33.1.49.95.63.43    maguy.parrinello@lrb.aphp.fr   
Principal Investigator: Jean-François JB BERGMANN, PhD         
Hopital Pitie-Salpetriere Recruiting
Paris, France, 75651
Contact: Catherine CL LUPIN    +33.1.42.16.10.95    catherine.lupin@psl.aphp.fr   
Principal Investigator: Anne AS SIMON, PhD         
Hopital Bichat Recruiting
Paris, France, 75018
Contact: Zélie ZJ JULIA    +33.1.40.25.70.57    zelie.julia@bch.aphp.fr   
Principal Investigator: Véronique VJ JOLY, PhD         
Hopital Saint Antoine Recruiting
Paris, France, 75012
Contact: Jean-Luc JL LAGNEAU    +33.1.49.28.24.86    jean-luc.lagneau@sat.aphp.fr   
Principal Investigator: Nadia NV VALIN, PhD         
Hopital Tenon Recruiting
Paris, France, 75020
Contact: Laurence LS SLAMA, PhD    +33.1.56.01.74.36    laurence.slama@tnn.aphp.fr   
Contact: Nadège NV VELAZQUEZ    +33.1.56.01.74.36    nadege.velazquez@tnn.aphp.fr   
Principal Investigator: Laurence LS SLAMA, PhD         
Hopital Cochin Recruiting
Paris, France, 75674
Contact: Marie-Pierre MP PIETRI    +33.1.58.41.21.34    marie-pierre.pietri@cch.aphp.fr   
Principal Investigator: Dominique DS SALMON, PhD         
Hopital Saint-Jean Roussillon Recruiting
Perpignan, France, 66046
Contact: Martine MM MALET    +33.4.68.61.61.43    recherche.clinique@ch-perpignan.fr   
Principal Investigator: Hugues HA AUMAITRE, PhD         
Hopital Rene Dubos Recruiting
Pontoise, France, 95303
Contact: Martine MD DESCHAUD    +33.1.30.75.47.24    martine.deschaud@ch-pontoise.fr   
Principal Investigator: Laurent LB BLUM, PhD         
C.H.R.A Recruiting
Pringy, France, 74374
Contact: Gaëlle GC CLAVERE    +33.4.50.63.67.93    gclavere@ch-annecy.fr   
Principal Investigator: Jean-Pierre JB BRU, PhD         
Hopital Civil Recruiting
Strasbourg, France, 67000
Contact: Patricia PF FISCHER    +33.3.69.55.05.01    patricia.fischer@chru-strasbourg.fr   
Principal Investigator: David DR REY, PhD         
Hopital Gustave Dron Recruiting
Tourcoing, France, 59208
Contact: Sylvie SV VANDAMME       svandamme@ch-tourcoing.fr   
Principal Investigator: Yazdan YY YAZDANPANAH, PhD         
Hopital Bretonneau Recruiting
Tours, France, 37044
Contact: Gaëlle GF FAJOLE    +33.2.47.47.37.14    g.fajole@chu-tours.fr   
Principal Investigator: Louis LB BERNARD, PhD         
Sponsors and Collaborators
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
Investigators
Principal Investigator: Laurence LS SLAMA, PhD Hospital TENON
Principal Investigator: Roland RL LANDMAN, PhD Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
  More Information

No publications provided

Responsible Party: Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
ClinicalTrials.gov Identifier: NCT01928407     History of Changes
Other Study ID Numbers: IMEA 040-DATA
Study First Received: June 19, 2013
Last Updated: August 20, 2013
Health Authority: France: Agence Nationale de Sécurité du Médicament et des produits de santé

Keywords provided by Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba:
naives, CD4 < 200 cell/mm3, Atazanavir, Darunavir

Additional relevant MeSH terms:
Communicable Diseases
Infection
Atazanavir
Darunavir
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on October 19, 2014